Second-Chance drug tested for transplant complications
NCT ID NCT02891395
Summary
This study tested whether the drug nilotinib could help control chronic graft-versus-host disease in patients who had already tried and failed treatment with imatinib. The trial involved 65 adults who had received stem cell transplants and developed this serious complication where donor cells attack the patient's body. Researchers gave nilotinib to patients who didn't respond to imatinib, measuring whether their symptoms improved over three months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT -VERSUS-HOST-DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Besançon
Besançon, France
-
CHU Bordeaux
Bordeaux, France
-
CHU Clémenceau
Caen, France
-
CHU Grenoble
Grenoble, France
-
CHU Hotel Dieu
Nantes, France
-
CHU Purpan
Toulouse, France
-
CHU Sart Tilman
Liège, Belgium
-
CHU d'Amiens
Amiens, France
-
CHU d'Angers
Angers, France
-
CHU de Clermont Ferrand
Clermont-Ferrand, France
-
CHU de Lyon
Lyon, France
-
CHU de Nice
Nice, France
-
CHU de STRASBOURG
Strasbourg, France
-
Centre Henri Becquerel
Rouen, France
-
Centre hospitalier et régional de Lille
Lille, France
-
Diseases of Blood Service HURIEZ hospital CHRU de LILLE
Lille, 59037, France
-
HIA de Percy
Clamart, France
-
Hopital Morvan
Brest, France
-
Hopital NECKER
Paris, France
-
Hôpital Saint Eloi
Montpellier, France
-
Hôpital pitié Salpetrière
Paris, France
-
Institut Paoli Calmettes
Marseille, France
Conditions
Explore the condition pages connected to this study.